Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique. 2006

Kenichiro Imura, and Yuji Ueda, and Takashi Hayashi, and Tsuyoshi Itoh, and Keiji Shimizu, and Hidemasa Tamai, and Yutaro Yano, and Kei Naito, and Junji Kohara, and Kazuki Nakane, and Yuko Matsuura, and Atsuko Takeda, and Takahisa Takeda, and Keiichi Kawai, and Hisakazu Yamagishi
Department of Surgery, Division of Digestive Surgery, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kyoto 602-8566, Japan.

Recently, dendritic cells (DCs) and DC-tumor cell hybrids (DC-tumor hybrids) have been used for cancer vaccine therapy in a clinical trial. DC-tumor hybrids combine the potent antigen-presenting capacity of DCs with the ability to present all tumor antigens expressed on tumor cells to T cells. We used DC-tumor hybrids as stimulator cells to induce tumor-specific cytotoxic T lymphocytes (CTLs) in vitro. DC-tumor hybrids were generated from human monocyte-derived DCs and human cancer-cell lines (GT3TKB, lung cancer; GCIY, gastric cancer) by our newly developed electrofusion technique, established and refined with the use of mouse cells. To evaluate the capacity of DC-tumor hybrids generated by our method to induce tumor antigen-specific CTLs, we performed a cytotoxic assay and an interferon-gamma release assay using CD8-dominant effector lymphocytes induced by them. DC-tumor hybrids more effectively induced tumor-specific primary T-cell response than did stimulation with DCs co-cultured with irradiated tumor cells overnight, irradiated tumor cells alone, or a mixture of DCs and irradiated tumor cells. DC-tumor hybrids were generated at a high fusion rate by our electrofusion technique. When CTLs were induced by DC-tumor hybrids in vitro, the high fusion rate did not contribute to the induction of CTLs with increased tumor-specific cytotoxicity. The addition of interleukin-12 to the culture medium did not augment the cytotoxicity of CTLs. Overall, our results suggest that DC-tumor hybrids effectively induce human tumor-specific CTLs and may thus be applicable for clinical trials of adoptive immunotherapy.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002459 Cell Fusion Fusion of somatic cells in vitro or in vivo, which results in somatic cell hybridization. Cell Fusions,Fusion, Cell,Fusions, Cell
D003713 Dendritic Cells Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION). Dendritic Cells, Interdigitating,Interdigitating Cells,Plasmacytoid Dendritic Cells,Veiled Cells,Dendritic Cells, Interstitial,Dendritic Cells, Plasmacytoid,Interdigitating Dendritic Cells,Interstitial Dendritic Cells,Cell, Dendritic,Cell, Interdigitating,Cell, Interdigitating Dendritic,Cell, Interstitial Dendritic,Cell, Plasmacytoid Dendritic,Cell, Veiled,Cells, Dendritic,Cells, Interdigitating,Cells, Interdigitating Dendritic,Cells, Interstitial Dendritic,Cells, Plasmacytoid Dendritic,Cells, Veiled,Dendritic Cell,Dendritic Cell, Interdigitating,Dendritic Cell, Interstitial,Dendritic Cell, Plasmacytoid,Interdigitating Cell,Interdigitating Dendritic Cell,Interstitial Dendritic Cell,Plasmacytoid Dendritic Cell,Veiled Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006822 Hybrid Cells Any cell, other than a ZYGOTE, that contains elements (such as NUCLEI and CYTOPLASM) from two or more different cells, usually produced by artificial CELL FUSION. Somatic Cell Hybrids,Cell Hybrid, Somatic,Cell Hybrids, Somatic,Cell, Hybrid,Cells, Hybrid,Hybrid Cell,Hybrid, Somatic Cell,Hybrids, Somatic Cell,Somatic Cell Hybrid
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Kenichiro Imura, and Yuji Ueda, and Takashi Hayashi, and Tsuyoshi Itoh, and Keiji Shimizu, and Hidemasa Tamai, and Yutaro Yano, and Kei Naito, and Junji Kohara, and Kazuki Nakane, and Yuko Matsuura, and Atsuko Takeda, and Takahisa Takeda, and Keiichi Kawai, and Hisakazu Yamagishi
March 2000, Biochimica et biophysica acta,
Kenichiro Imura, and Yuji Ueda, and Takashi Hayashi, and Tsuyoshi Itoh, and Keiji Shimizu, and Hidemasa Tamai, and Yutaro Yano, and Kei Naito, and Junji Kohara, and Kazuki Nakane, and Yuko Matsuura, and Atsuko Takeda, and Takahisa Takeda, and Keiichi Kawai, and Hisakazu Yamagishi
December 2006, Oncology reports,
Kenichiro Imura, and Yuji Ueda, and Takashi Hayashi, and Tsuyoshi Itoh, and Keiji Shimizu, and Hidemasa Tamai, and Yutaro Yano, and Kei Naito, and Junji Kohara, and Kazuki Nakane, and Yuko Matsuura, and Atsuko Takeda, and Takahisa Takeda, and Keiichi Kawai, and Hisakazu Yamagishi
July 2014, International journal of oncology,
Kenichiro Imura, and Yuji Ueda, and Takashi Hayashi, and Tsuyoshi Itoh, and Keiji Shimizu, and Hidemasa Tamai, and Yutaro Yano, and Kei Naito, and Junji Kohara, and Kazuki Nakane, and Yuko Matsuura, and Atsuko Takeda, and Takahisa Takeda, and Keiichi Kawai, and Hisakazu Yamagishi
August 2004, Cancer immunology, immunotherapy : CII,
Kenichiro Imura, and Yuji Ueda, and Takashi Hayashi, and Tsuyoshi Itoh, and Keiji Shimizu, and Hidemasa Tamai, and Yutaro Yano, and Kei Naito, and Junji Kohara, and Kazuki Nakane, and Yuko Matsuura, and Atsuko Takeda, and Takahisa Takeda, and Keiichi Kawai, and Hisakazu Yamagishi
April 2002, Annals of surgery,
Kenichiro Imura, and Yuji Ueda, and Takashi Hayashi, and Tsuyoshi Itoh, and Keiji Shimizu, and Hidemasa Tamai, and Yutaro Yano, and Kei Naito, and Junji Kohara, and Kazuki Nakane, and Yuko Matsuura, and Atsuko Takeda, and Takahisa Takeda, and Keiichi Kawai, and Hisakazu Yamagishi
June 2015, International journal of oncology,
Kenichiro Imura, and Yuji Ueda, and Takashi Hayashi, and Tsuyoshi Itoh, and Keiji Shimizu, and Hidemasa Tamai, and Yutaro Yano, and Kei Naito, and Junji Kohara, and Kazuki Nakane, and Yuko Matsuura, and Atsuko Takeda, and Takahisa Takeda, and Keiichi Kawai, and Hisakazu Yamagishi
March 1997, Japanese journal of cancer research : Gann,
Kenichiro Imura, and Yuji Ueda, and Takashi Hayashi, and Tsuyoshi Itoh, and Keiji Shimizu, and Hidemasa Tamai, and Yutaro Yano, and Kei Naito, and Junji Kohara, and Kazuki Nakane, and Yuko Matsuura, and Atsuko Takeda, and Takahisa Takeda, and Keiichi Kawai, and Hisakazu Yamagishi
April 1988, Transplantation proceedings,
Kenichiro Imura, and Yuji Ueda, and Takashi Hayashi, and Tsuyoshi Itoh, and Keiji Shimizu, and Hidemasa Tamai, and Yutaro Yano, and Kei Naito, and Junji Kohara, and Kazuki Nakane, and Yuko Matsuura, and Atsuko Takeda, and Takahisa Takeda, and Keiichi Kawai, and Hisakazu Yamagishi
May 1999, Cancer research,
Kenichiro Imura, and Yuji Ueda, and Takashi Hayashi, and Tsuyoshi Itoh, and Keiji Shimizu, and Hidemasa Tamai, and Yutaro Yano, and Kei Naito, and Junji Kohara, and Kazuki Nakane, and Yuko Matsuura, and Atsuko Takeda, and Takahisa Takeda, and Keiichi Kawai, and Hisakazu Yamagishi
October 1992, Cellular immunology,
Copied contents to your clipboard!